Get the latest on vaccine information, in-person appointments, video visits and more. Learn More
Fax: 832-825-1453 English, Romanian, Spanish
Ionela Iacobas, MD
|Baylor College of Medicine||fellowship||Pediatric Hematology Oncology||2010|
|The Brooklyn Hospital Center||residency||Pediatrics||2007|
|Albert Einstein College of Medicine||research fellow||Neurosciences||2004|
|Universitatea Ovidius, Facultatea de Medicina||medical school||Doctor of Medicine||2002|
Dr. Ionela Iacobas is the medical director of the Vascular Anomalies Center and Co-Director of the Pediatric Hematology-Oncology Vascular Anomalies Program at Texas Children's Hospital. Her main interest is to offer children and young adults with vascular anomalies state-of-the-art medical management in a comprehensive approach. Ranging from venous or lymphatic malformations to metastatic vascular tumors, the Vascular Anomalies Program uses anticoagulants (like low molecular weight heparin), immunosupressants (like sirolimus), chemotherapy, etc. to treat a large variety of vascular anomalies.
Dr. Iacobas believes that children with vascular tumors and malformations need more than just invasive procedures and medications, so her team involves the major supportive services (including physical therapy, social work, child life, psychology, pain management, orthotics - compression garments, support groups, etc).
As education and research in the vascular anomalies field are essential for best patient care, Dr. Iacobas is very active at the national level as Chair of the Education Committee of the Vascular Anomalies Specific Interest Group of ASPHO, where she is developing educational resources and a curriculum for hematology-oncology physicians who are interested in vascular anomalies.
American Board of Pediatrics
American Board of Pediatrics – Hematology/Oncology
|American Academy of Pediatrics (AAP)||Member|
|American Society of Pediatric Hematology and Oncology (ASPHO)||Member|
|International Society for the Study of Vascular Anomalies (ISSVA)||Member, Scientific Committee|
|Vascular Anomalies Specific Interest Group, American Society of Pediatric Hematology and Oncology (ASPHO)||Chair of the Education Committee|
Faculty Award for Excellence in Patient Care, Baylor College of Medicine, 2019
Grassia KL, Peterman CM, Iacobas I, Margolin JF, Bien E, Padhye B, Meyers RL, Adams DM. Clinical case series of pediatric hepatic angiosarcoma. Pediatr Blood Cancer. 2017 May 18.
Mahajan P, Margolin J, Iacobas I. Kasabach-Merritt Phenomenon: Classic Presentation and Management Options. Clin Med Insights Blood Disord. 2017 Mar 16.
Iacobas I, Klepper L, Kelly J, Ferry T, Dellinger MT. Meeting Report for the 2016 Conference on GLA and Gorham-Stout Disease. IBMS BoneKEy 2016; 13:847. doi:10.1038/bonekey.2016.76
Huho AN, Issaq N, Iacobas I, Elghetany MT, Lopez-Terrada D, Fisher K, Punia JN. A Rare Case of Pediatric Chronic Myelogenous Leukemia Presenting with Severe Thrombocytosis without Leukocytosis. Pediatr Dev Pathol. 2016 Jul 25. PMID: 27454200.
Iacobas I, Simon ML, Amir T, Gribbin CE, McPartland TG, Kaufman MR, Calderwood S, Nosher JL. Decreased vascularization of retroperitoneal kaposiform hemangioendothelioma induced by treatment with sirolimus explains relief of symptoms. Clin Imaging. 2015 May-Jun; 39(3):529-32. PMID: 25662209.
Sait S, Zaghloul N, Patel A, Shah T, Iacobas I, Calderwood S. Transfusion related iron overload in pediatric oncology patients treated at a tertiary care centre and treatment with chelation therapy. Pediatr Blood Cancer. 2014 Dec; 61(12):2319-20. PMID: 25154390.
Drolet BA, Trenor CC, Brandão LR, Chiu YE, Chun RH, Dasgupta R, Garzon MC, Hammill AM, Johnson CM, Tlougan B, Blei F, David M, Elluru R, Frieden IJ, Friedlander SF, Iacobas I, Jensen JN, King DM, Lee MT, Nelson S, Patel M, Pope E, Powell J, Seefeldt M, Siegel DH, Kelly M, Adams DM. Consensus-derived practice standards plan for complicated Kaposiform hemangioendothelioma. J Pediatr. 2013 Jul; 163(1):285-91. PMID: 23796341.
Iacobas I, Burrows PE. Chapter: Role of PTEN in Vascular Organization and Anomalies. PTEN: Structure, Mechanisms-of-Action, Role in Cell Signaling and Regulation. 2013; 211-233.
Iacobas I, Burrows PE, Adams DM, Sutton VR, Hollier LH, Chintagumpala MM. Oral rapamycin in the treatment of patients with hamartoma syndromes and PTEN mutation. Pediatr Blood Cancer. 2011 Aug; 57(2):321-3. PMID: 21360661.
Iacobas I, Burrows PE, Frieden IJ, Liang MG, Mulliken JB, Mancini AJ, Kramer D, Paller AS, Silverman R, Wagner AM, Metry DW. LUMBAR: association between cutaneous infantile hemangiomas of the lower body and regional congenital anomalies. J Pediatr. 2010 Nov; 157(5):795-801.e1-7. PMID: 20598318.
Iacobas I, Vats A, Hirschi KK. Vascular potential of human pluripotent stem cells. Arterioscler Thromb Vasc Biol. 2010 Jun; 30(6):1110-7. PMID: 20453170; PMCID: PMC2896478.
Duffy HS, Iacobas I, Hotchkiss K, Hirst-Jensen BJ, Bosco A, Dandachi N, Dermietzel R, Sorgen PL, Spray DC. The gap junction protein connexin32 interacts with the Src homology 3/hook domain of discs large homolog 1. J Biol Chem. 2007 Mar 30; 282(13):9789-96. PMID: 17284442.